Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer

Li, S.; Chen, Q.; Li, H.; Wu, Yanni; Feng, Junjie; Yan, Yi

doi:10.1007/s12094-017-1652-z

Cited by 29 publications

(37 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we used the CanPatrol technique to count and characterize CTCs in a single test . The CanPatrol technique characterizes and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes .…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, we used the CanPatrol technique to count and characterize CTCs in a single test [10][11][12][13][14][15][16]. The CanPatrol technique characterizes and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes [10][11][12][13][14][15][16]. Compared with the CellSearch platform, which uses anti-EpCAM-coated magnetic beads to capture CTCs, the CanPatrol technique uses an unbiased CTC isolation method that allows the isolation of CTCs that do not detectably express epithelial markers [10][11][12][13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

“…The CanPatrol technique characterizes and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes [10][11][12][13][14][15][16]. Compared with the CellSearch platform, which uses anti-EpCAM-coated magnetic beads to capture CTCs, the CanPatrol technique uses an unbiased CTC isolation method that allows the isolation of CTCs that do not detectably express epithelial markers [10][11][12][13][14][15][16]. For example, the CanPatrol technique was used to detect CTCs in patients with nasopharyngeal, breast, liver, gastric, colorectal and nonsmall-cell lung cancer, and three phenotypes of CTCs are present in all [10][11][12][13][14][15][16].…”

Section: Discussionmentioning

confidence: 99%

“…Counting and characterization of CTCs were performed using the CanPatrol CTC technique (SurExam, Guangzhou, China), as described in detail in previous studies [10][11][12][13][14][15][16]. Specifically, the CanPatrol CTC technique employs a filtration system comprising a filtration tube containing a calibrated membrane (8-lm-diameter pores; SurExam), a manifold vacuum plate with valve settings (SurExam), an E-Z 96 vacuum manifold (Omega, Norcross, GA, USA), and a vacuum pump (Auto Science, Tianjin, China).…”

Section: Isolation and Characterization Of Circulating Tumour Cellsmentioning

confidence: 99%

See 3 more Smart Citations

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Yang

Kong

et al. 2019

BJU International

View full text Add to dashboard Cite

Objectives To identify biomarkers that predict the response to standard androgen deprivation therapy (ADT) of patients newly diagnosed with metastatic castration‐sensitive prostate cancer (CSPC) in order to improve therapeutic decision‐making, and to investigate whether the characterization of baseline circulating tumour cells (CTCs) would predict the effective period of standard ADT. Materials and Methods The study included 108 patients newly diagnosed with high‐volume metastatic CSPC. Enumeration and characterization of patients’ baseline CTCs (CTCs+ and CTCs−, indicating detectable and undetectable CTCs, respectively) were performed using the CanPatrol technique, which detects markers of the epithelial to mesenchymal transition (EMT) in CTCs, and classifies CTCs into epithelial, biophenotypic and mesenchymal phenotypes. Results After a median follow‐up of 24 months, 90 patients (83.3%) progressed to castration‐resistant prostate cancer (CRPC), 93 patients (86.1%) had detectable CTCs, and the median number of CTCs was 4. The rate of progression to CRPC was significantly higher for patients with mesenchymal CTCs+ than for patients with CTCs+/mesenchymal CTCs− and CTCs− (93.1% vs 71.4% and 73.3%; P = 0.013). The median time to CRPC for patients with mesenchymal CTCs+ was significantly shorter than for those with CTCs+/mesenchymal CTCs− and CTCs− (10.5 months vs 18.0 and 14.0 months; P = 0.003). Multivariate Cox regression analysis suggested that the CTC phenotype was the only independent prognostic factor influencing the progression of disease from CSPC to CRPC. Conclusions Characterization of baseline CTCs according to the EMT phenotype predicted the effective period of standard ADT for patients newly diagnosed with metastatic CSPC. These findings are important for counselling patients and designing clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Isolation and Characterization Of Circulating Tumour Cellsmentioning

confidence: 99%

See 2 more Smart Citations

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Yang

Kong

et al. 2019

BJU International

View full text Add to dashboard Cite

show abstract

“…The expression of this receptor in CTCs has been shown to be predictive of prognosis in patients with NSCLC who are undergoing second‐line treatment with AXD929 . The EMT phenotype and expression of GALC, OCT4, and TTF‐1 messenger RNA (mRNA) in CTCs also have been found to be predictive of poor prognosis in patients with NSCLC …”

Section: Introductionmentioning

confidence: 99%

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Jin

Chen

Lan³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real‐time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a “liquid biopsy”) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.

show abstract

Mutational Analysis of OCT4+ and OCT4− Circulating Tumour Cells by Single Cell Whole Exome Sequencing in Stage I Non-Small Cell Lung Cancer Patients

Yan

Chang

et al. 2021

J. Shanghai Jiaotong Univ. (Sci.)

View full text Add to dashboard Cite

Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer

Abstract: The findings suggest that identification of CTCs by EMT markers as well as evaluation of OCT4 expression status by assessment of OCT4 expression in CTCs could serve as potential adjuncts for evaluating metastasis and prognosis in NSCLC patients.

Cited by 29 publications

References 34 publications

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration‐sensitive prostate cancer

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Mutational Analysis of OCT4+ and OCT4− Circulating Tumour Cells by Single Cell Whole Exome Sequencing in Stage I Non-Small Cell Lung Cancer Patients

Contact Info

Product

Resources

About